日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy of a Serotonin-Norepinephrine Reuptake Inhibitor as a Treatment for Meniere Disease: A Randomized Clinical Trial

血清素-去甲肾上腺素再摄取抑制剂治疗梅尼埃病的疗效:一项随机临床试验

Rizk, Habib; Monaghan, Neil P; Shah, Sunny; Liu, Yuan; Keith, Brian A; Jeong, Seth; Nguyen, Shaun A

N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants

N-(3-甲氧基苯基)-6-(7-(1-甲基-1H-吡唑-4-基)咪唑并[1,2-a]吡啶-3-基)吡啶-2-胺是 FLT3-ITD 和 BCR-ABL 通路的抑制剂,可有效抑制 FLT3-ITD/D835Y 和 FLT3-ITD/F691L 二级突变体

Xiuqi Wang, Rosa Anna DeFilippis, Yuet-Kin Leung, Neil P Shah, Hong-Yu Li

Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

细胞周期蛋白 D3 的复发性突变导致急性髓系白血病对 FLT3 抑制剂产生临床耐药性

Catherine C Smith, Aaron D Viny, Evan Massi, Cyriac Kandoth, Nicholas D Socci, Franck Rapaport, Matthieu Najm, Juan S Medina-Martinez, Elli Papaemmanuil, Theodore C Tarver, Henry H Hsu, Mai H Le, Brian West, Gideon Bollag, Barry S Taylor, Ross L Levine, Neil P Shah

Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor

通过对 NEK2 抑制剂进行结构优化,发现咪唑并[1,2-a]吡啶噻吩衍生物可作为急性髓系白血病的 FLT3 和 FLT3 突变体抑制剂

Lingtian Zhang, Naga Rajiv Lakkaniga, Jaideep B Bharate, Nicholas Mcconnell, Xiuqi Wang, Anupreet Kharbanda, Yuet-Kin Leung, Brendan Frett, Neil P Shah, Hong-Yu Li

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells

丙咪嗪蓝敏感且选择性地靶向 FLT3-ITD 阳性急性髓系白血病细胞

Jonathan Metts, Heath L Bradley, Zhengqi Wang, Neil P Shah, Reuben Kapur, Jack L Arbiser, Kevin D Bunting

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia

MERTK/FLT3 抑制剂 MRX-2843 可克服急性髓系白血病中导致耐药的 FLT3 突变

Katherine A Minson, Catherine C Smith, Deborah DeRyckere, Clara Libbrecht, Alisa B Lee-Sherick, Madeline G Huey, Elisabeth A Lasater, Gregory D Kirkpatrick, Michael A Stashko, Weihe Zhang, Craig T Jordan, Dmitri Kireev, Xiaodong Wang, Stephen V Frye, H Shelton Earp, Neil P Shah, Douglas K Graham

MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction

MEK依赖性负反馈是BCR-ABL介导的癌基因成瘾的基础。

Jennifer Asmussen ,Elisabeth A Lasater, Cheryl Tajon, Juan Oses-Prieto, Young-Wook Jun, Barry S Taylor, Alma Burlingame, Charles S Craik, Neil P Shah

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

用于合理设计多药理学的双激酶-溴结构域抑制剂

Pietro Ciceri, Susanne Müller, Alison O'Mahony, Oleg Fedorov, Panagis Filippakopoulos, Jeremy P Hunt, Elisabeth A Lasater, Gabriel Pallares, Sarah Picaud, Christopher Wells, Sarah Martin, Lisa M Wodicka, Neil P Shah, Daniel K Treiber, Stefan Knapp

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

BCL6 介导的 p53 抑制对于慢性粒细胞白血病中的白血病干细胞存活至关重要

Christian Hurtz, Katerina Hatzi, Leandro Cerchietti, Melanie Braig, Eugene Park, Yong-mi Kim, Sebastian Herzog, Parham Ramezani-Rad, Hassan Jumaa, Martin C Müller, Wolf-Karsten Hofmann, Andreas Hochhaus, B Hilda Ye, Anupriya Agarwal, Brian J Druker, Neil P Shah, Ari M Melnick, Markus Müschen

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

序贯 ABL 激酶抑制剂疗法选择具有改变的致癌效力的复合药物耐药 BCR-ABL 突变

Neil P Shah, Brian J Skaggs, Susan Branford, Timothy P Hughes, John M Nicoll, Ronald L Paquette, Charles L Sawyers